Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2015.12.062 ◽

2016 ◽

Vol 11 (2) ◽

pp. S36-S37 ◽

Cited By ~ 7

Author(s):

Karen L. Reckamp ◽

Jeffrey R. Infante ◽

George R. Blumenschein ◽

Heather Wakelee ◽

Corey A. Carter ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

Translational Oncology ◽

10.1016/j.tranon.2021.101338 ◽

2022 ◽

Vol 17 ◽

pp. 101338

Author(s):

Xinru Chen ◽

Xiangchan Hong ◽

Gang Chen ◽

Jinhui Xue ◽

Jie Huang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Alk Inhibitor ◽

Immune Inflammation

Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

Journal of Thoracic Disease ◽

10.21037/jtd.2016.10.57 ◽

2016 ◽

Vol 8 (10) ◽

pp. E1287-E1292 ◽

Cited By ~ 2

Author(s):

Ivana Sullivan ◽

David Planchard

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study

Clinical Pharmacokinetics ◽

10.1007/s40262-021-01015-z ◽

2021 ◽

Author(s):

Joseph Chen ◽

Melissa T. O’Gorman ◽

Lee P. James ◽

Karen J. Klamerus ◽

Ganesh Mugundu ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Multiple Dosing ◽

Anaplastic Lymphoma ◽

Alk Positive

Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases

Annals of Oncology ◽

10.1093/annonc/mdv128.06 ◽

2015 ◽

Vol 26 ◽

pp. i57 ◽

Cited By ~ 8

Author(s):

D. Kerstein ◽

S. Gettinger ◽

K. Gold ◽

C.J. Langer ◽

A.T. Shaw ◽

...

Keyword(s):

Lung Cancer ◽

Brain Metastases ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy

Molecular Diagnosis & Therapy ◽

10.1007/bf03262202 ◽

2012 ◽

Vol 16 (3) ◽

pp. 143-150 ◽

Cited By ~ 22

Author(s):

Eunhee S. Yi ◽

Jin-Haeng Chung ◽

Kimary Kulig ◽

Keith M. Kerr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Gene Rearrangement ◽

Small Cell ◽

Inhibitor Therapy ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Sequential Anaplastic Lymphoma Kinase (ALK) Inhibitor Prolongs Overall Survival in Patients with ALK-Fusion Advanced Non-Small-Cell Lung Cancer

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3937 ◽

2019 ◽

Author(s):

A.C.C. Huang ◽

M.C. Ko ◽

C.-H.S. Kuo

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000566 ◽

2015 ◽

Vol 10 (7) ◽

pp. 1058-1066 ◽

Cited By ~ 39

Author(s):

Makoto Nishio ◽

Haruyasu Murakami ◽

Atsushi Horiike ◽

Toshiaki Takahashi ◽

Fumihiko Hirai ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase I Study ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma

5P Targeted degradation of anaplastic lymphoma kinase by target degraducer in non-small cell lung cancer

Annals of Oncology ◽

10.1016/s0923-7534(21)00167-8 ◽

2016 ◽

Vol 27 ◽

pp. ix2

Author(s):

J.Y. Hwang ◽

C.-H. Park ◽

D.H. Lee ◽

C.H. Kang ◽

C.O. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Visual Effects in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib

Annals of Oncology ◽

10.1016/s0923-7534(20)32041-x ◽

2012 ◽

Vol 23 ◽

pp. xi44

Author(s):

P.-C. Yang ◽

R. Salgia ◽

B. Solomon ◽

A.T. Shaw ◽

D.R. Camidge ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Visual Effects ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Nsclc Patients